Are you trying to define the mechanism of action of your Antibody?
Roche Glycart have focussed their attention on GA101, a type II CD20 antibody and compared its structural information with rituximab (a type II antibody) to explain its function. Comparisons were made of the two antibodies with regards to binding site and crystal structures, allowing a model of binding to be proposed and the difference between type I and II antibodies to be discussed. This data was presented at the 7th annual European antibody congress 2011 by Dr Christian Klein, Head of Oncology Programs in PRED.
Do you want to find out more?